Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Current Investments (2016 - 2025)

China Pharma Holdings filings provide 16 years of Cash & Current Investments readings, the most recent being $345112.0 for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 44.95% to $345112.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $345112.0, a 44.95% decrease, with the full-year FY2025 number at $345112.0, down 44.95% from a year prior.
  • Cash & Current Investments hit $345112.0 in Q4 2025 for China Pharma Holdings, up from $300000.0 in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $4.9 million in Q4 2021 to a low of $300000.0 in Q3 2025.
  • Median Cash & Current Investments over the past 5 years was $870395.5 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 642.96% in 2022 and later plummeted 68.59% in 2023.
  • China Pharma Holdings' Cash & Current Investments stood at $4.9 million in 2021, then tumbled by 58.22% to $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plummeted by 55.97% to $626879.0 in 2024, then crashed by 44.95% to $345112.0 in 2025.
  • The last three reported values for Cash & Current Investments were $345112.0 (Q4 2025), $300000.0 (Q3 2025), and $625032.0 (Q2 2025) per Business Quant data.